Stocktoria

INTEGRA LIFESCIENCES HOLDINGS CORP IART

Nasdaq · stock · Surgical & Medical Instruments & Apparatus · website · IPO 1995-08-16 · LEI

INTEGRA LIFESCIENCES HOLDINGS CORP financials (annual)

Revenue
$992.1M $1.19B $1.47B $1.52B $1.37B $1.54B $1.56B $1.54B $1.61B $1.64B 2016201720182019202020212022202320242025
Net income
$74.6M $64.7M $60.8M $50.2M $133.9M $169.1M $180.6M $67.7M -$6.9M -$516.5M 2016201720182019202020212022202320242025
Free cash flow
$69.1M $71.0M $121.9M $161.9M $164.9M $264.4M $222.1M $73.1M $25.0M -$31.1M 2016201720182019202020212022202320242025

Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$1.6B$1.6B$1.5B$1.6B$1.5B$1.4B$1.5B$1.5B$1.2B$992.1M
Gross profit—————$851.0M$952.9M$900.9M$752.7M$643.0M
R&D expense———————$78.0M$63.5M$58.2M
SG&A expense$699.7M$717.0M$656.6M$616.3M$637.4M$594.5M$687.6M$690.7M$624.1M$455.6M
Operating income-$493.4M$28.4M$111.5M$238.9M$197.2M$151.4M$93.8M$111.0M$44.8M$115.3M
Interest expense——$51.4M$49.6M$50.4M$71.6M$54.0M$64.7M$35.0M$25.8M
Income tax-$47.0M-$11.3M$13.3M$33.3M$45.6M-$40.4M$9.9M-$3.4M-$53.4M$15.8M
Net income-$516.5M-$6.9M$67.7M$180.6M$169.1M$133.9M$50.2M$60.8M$64.7M$74.6M
EPS (diluted)$-6.74$-0.09$0.84$2.16$1.98$1.57$0.58$0.72$0.82$0.94
Operating cash flow$50.4M$129.4M$140.0M$264.5M$312.4M$203.8M$231.4M$199.7M$114.5M$116.4M
Free cash flow-$31.1M$25.0M$73.1M$222.1M$264.4M$164.9M$161.9M$121.9M$71.0M$69.1M
Cash & equivalents$235.0M$246.4M$276.4M$456.7M$513.4M$470.2M$198.9M$138.8M$174.9M$102.1M
Inventory$492.7M$429.1M$389.6M$324.6M$317.4M$310.1M$316.1M$280.3M$296.3M$217.3M
Total assets$3.6B$4.0B$3.8B$3.9B$3.8B$3.6B$3.3B$3.1B$3.2B$1.8B
Total liabilities$2.6B$2.5B$2.2B$2.1B$2.1B$2.1B$1.9B$1.7B$2.2B$968.3M
Shareholders' equity$1.0B$1.5B$1.6B$1.8B$1.7B$1.5B$1.4B$1.4B$962.3M$839.7M

Growth · year-over-year · Revenue CAGR 5.7%

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue growth+1.5%+4.5%-1.0%+1.0%+12.4%-9.6%+3.1%+23.9%+19.8%—
Net income growth—-110.3%-62.5%+6.8%+26.3%+166.7%-17.4%-6.1%-13.2%—
EPS growth—-110.7%-61.1%+9.1%+26.1%+170.7%-19.4%-12.2%-12.8%—
Free cash flow growth-224.4%-65.8%-67.1%-16.0%+60.3%+1.9%+32.8%+71.7%+2.8%-17.4%

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.